---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066935"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:10:06.680318+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q1 revenue $17.5M (-9% YoY); reaffirms FY25 guidance $70-75M; lowers expense guide

## Summary
- Total revenue $17.5M, down 9% YoY; Surgical Glaucoma $17.1M (-6% YoY); Dry Eye $0.4M (-60% YoY).
- Gross margin 86% flat YoY; net loss $14.2M ($0.28 loss per share) vs $16.3M loss in prior year.
- Reaffirms FY25 revenue guidance $70-75M (decline 6-12% YoY); lowers adjusted op ex guide to $101-105M.
- Tariffs on China-made products seen adding $3.5-4.5M to 2025 COGS; impact larger in H2 2025.
- Launched OMNI Edge with TruSync technology at ASCRS April 2025; TearCare reimbursement not assumed in 2025.

## SEC filing metadata
- accession: 0000950170-25-066935
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017025066935/0000950170-25-066935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017025066935/sght-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066935
- JSON: https://secwatch.observer/filing/0000950170-25-066935.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.